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SUMMARY – The purpose of this study was to determine the prevalence of allele and genotype 
variants of the follicle-stimulating hormone receptor (FSHR) gene polymorphic region at position 
Asn680Ser in the Albanian male population and associate them with the clinical parameters of infer-
tility. The study included 114 infertile men (mean age 35.04±5.85 years) stratified according to the 
level of spermatogenetic impairment (oligoasthenozoospermia, asthenozoospermia and normosper-
mia) and 112 fertile men (mean age 36.44±7.05 years) with normal semen parameters. Genotyping of 
the FSHR gene at position 680 was performed by TaqMan genotyping assay. All the participants 
underwent semen analysis, and serum reproductive hormones (FSH, luteinizing hormone, prolactin 
and testosterone) were also measured. The FSHR Asn680Ser genotype frequencies were as follows: 
Asn/Ser 42%, Ser/Ser 33.9% and Asn/Asn 24.1% in the control group, and Asn/Ser 56.1%, Ser/Ser 
22.8% and Asn/Asn 21.1% in the whole group of infertile men (χ2-test: P=0.08). There was no statis-
tically significant correlation between serum hormone levels and semen characteristics or between 
fertility status and FSHR Asn680Ser gene variants in the control group and the group of infertile 
men. However, adjusted logistic regression analysis (age, body mass index, smoking and alcohol as 
covariates) revealed increased odds ratio for male infertility among heterozygous Asn/Ser genotype 
carriers associated with lower values of semen parameters (normal morphology, concentration, total 
sperm count and motility). In conclusion, our case-control study further confirmed previous reports 
on no significant association between the FSHR Asn680Ser polymorphisms and male infertility. 
Nevertheless, the data presented herein indicate that the Asn/Ser genotype may increase the risk of 
male infertility in Albanian population.
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Introduction
Normal function of cells involved in spermatogen-
esis, including the production of follicle-stimulating 
hormone (FSH) by these cells, is dependent on the 
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FSH receptor (R) gene expression1,2. However, the im-
pact of FSHR gene variants including the single nu-
cleotide polymorphisms (SNPs) on male fertility is 
currently not yet well understood. The human FSHR 
gene spans a region of 54 kb, consists of ten exons and 
nine introns, and maps to chromosome 2q. The first 
nine exons encode the extracellular domain, whereas 
the transmembrane and the intracellular receptor do-
mains are encoded by exon 10 of the FSHR gene3. 
Mutation screening of the FSHR gene revealed vari-
ous SNPs both in the promoter region and the coding 
region4-6. The most studied SNP in the promoter 
 region is located at position c.-29 (c.-29 G>A, 
rs1394205), while the two common SNPs located 
in exon 10 (c.919A>G, p.Thr307Ala, rs6165 and 
c.2039A>G, p.Asn680Ser, rs6166) are in strong link-
age disequilibrium, yielding two distinct allelic vari-
ants, Thr307-Asn680 and Ala307-Ser680, with the 
latter representing approximately 40% of FSH recep-
tor alleles worldwide4-6.
Up to date, several case-control studies and their 
meta-analyses were conducted to evaluate the associa-
tion between the FSHR polymorphic regions and 
male infertility7-12. Although mostly inconclusive, 
some of them revealed significant difference in the dis-
tribution of FSHR 2039A>G allelic variants between 
infertile men and fertile healthy controls, thus showing 
that ethnic differences could be contributory7,12-14. Be-
cause no study addressing the effect of FSHR 
2039A>G polymorphism on male (in)fertility in Al-
banian population has been conducted so far, we ana-
lyzed the allelic and genotype distribution of this poly-
morphic region and their association with serum re-
productive hormones and semen quality parameters in 
114 infertile men and 112 proven fathers from the 
Dukagjin region in the Republic of Kosovo.
Materials and methods
Study population
A total of 114 infertile male patients were included 
in this study. All patients presented with a history of 
unexplained primary infertility and were stratified into 
oligozoospermic (sperm count <15x106 spermatozoa 
per mL of ejaculate; n=67), normoasthenozoospermic 
(sperm count ≥15x106 spermatozoa per mL of ejacu-
late, progressive motility PR (A+B) % <32; n=28) and 
normospermic (normal semen quality; n=19) infertile 
men groups according to the World Health Organiza-
tion criteria (WHO, 2010). Infertility was defined as 
the inability to conceive despite 24-month unprotect-
ed intercourse with the same partner. All patients had 
a fertile female partner proven by extensive fertility 
evaluation. Participants with genital tract pathologies, 
leukocytospermia (more than 106 white blood cells per 
mL of ejaculate), positive mixed agglutination reaction 
and Y chromosome microdeletion or karyotype abnor-
malities were not included in the study. Control group 
consisted of 112 proven fertile men (fathered at least 
one child without assisted reproductive technologies) 
with normal semen parameters according to the WHO 
guidelines (WHO, 2010). All patients and controls 
were ethnic Albanians from the Dukagjin region in 
the Republic of Kosovo. All participants gave a written 
informed consent, while the institutional Ethics Com-
mittee approved the study protocol in accordance with 
the Declaration of Helsinki.
Medical evaluations
Upon inclusion, all participants underwent medical 
examination, which included a detailed reproductive 
history, determination of testicular size by ultrasonog-
raphy, urine analysis and complete blood count, bio-
chemical profile and thyroid function test, measure-
ment of serum FSH, luteinizing hormone (LH), tes-
tosterone (T) and prolactin (PRL) levels by BioMéri-
eux Mini Vidas Automated Immunoassay Analyzer 
(bioMérieux S.A., Marcy l’Etoile, France) and semen 
analysis according to the WHO recommendations of 
2010. At least two semen samples were provided by 
each participant after an abstinence period of 3-4 days 
one month apart.
Genotyping
Genomic DNA was extracted from peripheral 
blood leukocytes using the whole blood PureLink™ 
Genomic DNA Mini Kit (Invitrogen, Life Technolo-
gies Corporation, Carlsbad, CA, USA). The FSHR 
gene polymorphism at codon 680 (N680S, rs6166. 
2039A>G) was analyzed by the TaqMan allelic dis-
crimination assay (Assay ID: C___2676874_10; cat. 
number 4351376; Lot Number: P130805-002H05; 
Assay Mix Concentration; 40X; Forward Primer Con-
centration 36 μM; Reverse Primer Concentration 36 
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μM; concentration of forward and reverse primer: 900 
nM, probe concentration: 200 nM FAM™/VIC® 
dyes; Context Sequence [VIC/FAM]:AGGGACAA
GTATGTA AGTG G A ACCA [ C / T ] TG GT-
GACTCTGGGACTGAAGAGCA (Life Technolo-
gies Corporation, Carlsbad, CA, USA) using the Ap-
plied Biosystems Real-Time PCR System 7500 (Ap-
plied Biosystems, Foster City, CA, USA). Each poly-
merase chain reaction (PCR) (25 μL) contained 1.25 
μL TaqMan® SNP Genotyping Assay (X20 dilution), 
12.50 μL TaqMan Universal PCR Master Mix II No 
AmpErase UNG (2X dilution) (Applied Biosystems, 
Foster City, CA, USA), 5 μL of genomic DNA and 
6.25 μL of DNase/RNase free water. PCR was carried 
out in two steps: absolute quantification and allelic 
discrimination. For absolute quantification, the cycles 
were as follows: AmpliTaq Gold Enzyme activation 
at 95 °C for 10 min (1 cycle); 40 cycles: denaturation 
at 92 °C for 15 s, and annealing/extension at 60 °C 
for 1 min. The results were verified by Applied Biosys-
tems Real-Time PCR System 7500 allelic discrimina-
tion software (Applied Biosystems, Foster City, CA, 
USA).
Statistical analysis
Mean, standard deviation, median and 5-95th per-
centiles were calculated for general characteristics [age, 
body mass index (BMI)] and main outcome variables 
(hormonal and seminal variables, total testis volume) 
using SPSS software version 22 (SPSS Inc., Chicago, 
IL, USA). Before statistical analysis, data were tested 
for normal distribution using the Kolmogorov-
Smirnov and Shapiro-Wilk test. For data not normal-
ly distributed, the Kruskal-Wallis test was applied. 
Hardy-Weinberg equilibrium was assessed by χ2 anal-
ysis. Odds ratio (OR) and 95% confidence interval 
(95% CI) were calculated to measure the strength of 
the association, where applicable. Logistic regression 
analysis was used to adjust statistical findings for con-
founding factors (age, BMI, smoking and alcohol con-
sumption). Clinical data were compared among differ-
ent genotypes by one-way ANOVA and χ2-test, where 
appropriate. Genotype association tests were per-
formed under co-dominant, dominant, recessive and 
over-dominant genetic models. A nominal level of sig-
nificance P<0.05 was accepted and corrected accord-
ing to Bonferroni procedure (the corrected level of 
significance is: Pc=0.05/N; N, number of independent 
comparisons). All reported P values were two-sided 
and uncorrected unless stated otherwise.
Results
Demographic and clinical characteristics  
of study participants
Table 1 shows the mean and median values of de-
mographic and clinical parameters in infertile men 
and control group. As can be seen, no statistically sig-
nificant differences were found in age (control: 
36.44±7.047 years; infertile men group: 35.04±5.854 
years), BMI and alcohol consumption between the 
control and infertile men groups after Bonferroni cor-
rection for multiple testing was applied [one-way 
ANOVA/independent sample t test; Kruskal Wallis /
Mann-Whitney U test Pc=0.05/55=9.1x10-4; taking 
into account the number of independent measure-
ments (eleven) and tested study samples (five)]. How-
ever, the number of ever smokers was statistically 
higher in overall (P=0.0001), normoasthenozoosper-
mic (P=0.001) and normospermic (P=0.004) infertile 
men subgroups relative to control participants [χ2-test 
Pc=0.05/10=0.005; taking into account the number of 
independent measurements (two) and tested study 
samples (five)].
Genotype distribution and allele frequencies
The results of statistical analysis of the distribution 
of Asn680Ser FSHR gene polymorphism genotype 
and allele frequencies between infertile men (n=114) 
and controls (n=112) are shown in Table 2. The allele 
frequencies were 54.91% Ser (S) and 45.09% Asn (N) 
in the control group, and 50.88 % Ser and 49.12% Asn 
in the overall infertile men group (P=0.39, χ2-test). No 
significant differences in allele distribution relative to 
control were observed for any of the infertility sub-
groups (i.e. oligoastheno-, normoastheno- and normo-
spermia) analyzed in the study. In addition, no signifi-
cant difference was observed in genotype distribution 
between control and overall infertile men group, and 
the genotypes were in Hardy-Weinberg equilibrium in 
both groups (infertile men group: χ2=1.73, df=1, 
P=0.19; control group: χ2=2.61, df=1, P=0.11). Fur-
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bution between the oligoazoospermic infertile group 
and control group was lost when Bonferroni correction 
for multiple testing was applied.
Association of N680S FSHR gene polymorphism  
with infertility
Table 3 shows the results of contingency table (χ2-
test) analysis of Asn680Ser FSHR genotype and allele 
distribution among the studied groups. As can be seen, 
OR between the Asn and Ser allele for development of 
infertility was higher in the overall, as well as in the 
oligo- and normoasthenozoospermic infertile men 
groups relative to control group, thus indicating the 
Ser allele as being protective against infertility. How-
ever, the effect did not reach statistical significance 
 after Bonferroni correction for multiple testing was 
applied.
Crude and adjusted (age, BMI, smoking and alco-
hol as covariates) logistic regression analysis revealed 
an increased risk of infertility in heterozygous Asn/Ser 
genotype carriers in the overall (ORA=2.36; 95% CI: 
1.19-4.67) and oligoasthenozoospermic (ORA=2.745; 
95% CI: 1.24-6.07) infertile men groups when com-
pared with Ser/Ser genotype carriers. Again, no sig-
nificant association was observed after Bonferroni cor-
rection for multiple testing was applied. Interestingly, 
relative to Ser/Ser genotype carriers, the homozygous 
Asn/Asn genotype carriers in the normoasthenozoo-
spermic infertile men group exhibited higher 
(ORA=3.28; 95% CI: 0.87-12.30) nonsignificant risk 
of infertility compared to Asn/Ser (ORA=2.55; 95% 
CI: 0.76-8.56) genotype carriers. No genetic associa-
tions between FSHR Asn680Ser polymorphism and 
tested reproductive parameters reached Bonferroni-
corrected statistical significance level irrespective of 
whether the groups were analyzed under the co-dom-
inant, dominant, recessive or over-dominant genetic 
model [Pc=0.05/20=0.0025, taking into account the 
number of studied groups (five) and tested genotype 
models (four)]. Nevertheless, the best-fitting over-
dominant genetic model (Asn/Ser vs. Ser/Ser + Asn/
Asn) further implicated an increased risk of male in-
fertility in heterozygous Asn/Ser genotype carriers ei-
ther in the overall infertile men group (ORA=2.032; 
95% CI: 1.138-3.626) or when subgrouping them ac-
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Table 3. Contingency table analysis for Asn680Ser FSHR genotype and allele distribution 
between the subgroups of infertile men and control group
Variable Frequencyn (%)
Contingency tables
OR (95% CI) P
a
Infertile men (N=114)
Ser/Ser 26 (22.8) 0.5754 (0.3199-1.0347) 0.06
Asn /Ser 64 (56.1) 1.7702 (1.0451-2.9984) 0.03
Asn/Asn 24 (21.1) 0.8395 (0.4495-1.5679) 0.58
Ser 116 (50.88) 0.8505 (0.5876-1,2309) 0.39
Asn 112 (49.12) 1.1758 (0.8124-1.7018)
Oligoasthenozoospermia (n=67)
Ser/Ser 14 (20.9) 0.5144 (0.2537-1.0432) 0.063
Asn /Ser 42 (62.79 2.3234 (1.2483-4.3245) 0.007
Asn/Asn 11 (16.4) 0.6184 (0.284-1.3463) 0.22
Ser 70 (52.24) 0.8981 (0.5847-1.3795) 0.62
Asn 64 (47.76) 1.1134 (0.7249-1.7102)
Normoasthenozoospermia (n=28)
Ser/Ser 5 (17.9) 0.4233 (0.1491-1.2016) 0.10
Asn /Ser 13 (46.4) 1.1986 (0.5215-2.7546) 0.67
Asn/Asn 10 (35.7) 1.749 (0.7211-4.2421) 0.21
Ser 23 (41.07) 0.5723 (0.316-1.0365) 0.06
Asn 33 (58.93) 1.7473(0.9648-3.1644)
Normospermia (n=19)
Ser/Ser 7 (36.8) 1.136 (0.4134-3.1217) 0.81
Asn /Ser 9 (47.4) 1.2447 (0.4692-3.3019) 0.66
Asn/Asn 3 (15.8) 0.5903 (0.1598-2.181) 0.43
Ser 23 (60.53) 1.2591 (0.6242-2.5398) 0.52
Asn 15 (39.47) 0.7942 (0.3937-1.6021)
OR = odds ratio with 95% CI; 95% = 95% confidence interval; aP values for individual genotype and allele com-
parisons between the subgroups of infertile men and control group; Bonferroni threshold for correction for mul-
tiple testing was estimated as Pc=0.05/12=0.004, taking into account the number of genotypes (three) and study 
samples tested (four). Note: data for control group are not shown.
Asn = asparagine; Ser = serine
Association of N680S FSHR gene polymorphism  
and reproductive hormones
Serum FSH level in the infertile men group (6.85± 
5.85) was higher relative to control group (4.71±2.27) 
but the difference did not reach statistical significance 
after Bonferroni correction for multiple testing was 
applied (P=0.01<Pc=0.05/55=9.1x10-4). Similar results 
were obtained in the oligoasthenozoospermic, nor-
moasthenozoospermic and normospermic infertile 
men subgroups compared to control group. Contrary, 
serum prolactin level was significantly (P=0.0006) 
higher in the overall infertile men group compared to 
control group (15.85±8.80 and 12.26±5.34, respective-
ly). However, the difference did not reach statistical 
 significance in any of the infertile men subgroups 
 analyzed. The overall infertile men group also showed 
lower LH (4.11±2.18 and 4.46±2.59, respectively) and 
testosterone (4.73±2.36 and 12.26±5.34, respectively) 
serum levels relative to control group. Again, the 
 differences did not reach statistical significance 
(P=0.48<Pc=0.05/55=9.1x10-4) for LH levels between 
these two groups or between any other infertile men 
subgroup and control group, while testosterone 
 exhibited a significantly lower serum level only in the 
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Table 4. Risk of infertility and Asn680Ser FSHR gene polymorphism among infertile men included in the study




Crude OR (95% 
CI)
P Logistic regressionORA (95% CI)
P
Infertile men (N=114)
Ser/Ser 38 (33.9) 26 (22.8) 1.0 (Reference) 0.084a 1.0 (Reference) 0.042a
Co-dominant Asn/Ser 47 (42.0) 64 (56.1) 1.99 (1.07- 3.72) 0.03b 2.36 (1.19-4.67) 0.01b
Asn/Asn 27 (24.1) 24 (21.1) 1.30 (0.62-2.73) 0.49b 1.40 (0.62-3.15) 0.42b
Dominant Ser/Ser 38(33.9) 26 (22.8) 1.0 (Reference) 1.0 (Reference)
Asn/Asn + Asn/Ser 74 (66.1) 88 (77.2) 1.74 (0.97 - 3.13) 0.065b 1.99 (1.05 - 3.80) 0.035
Recessive Ser/Ser +Asn/Ser 85 (75.9) 90 (79) 1.0 (Reference) 1.0 (Reference)
Asn/Asn 27 (24.1) 24 (21.1) 0.84 (0.45 - 1.57) 0.583b 0.81 (0.41 - 1.60) 0.548b
Over-dominant Ser/Ser + Asn/Asn 65 (58.0) 50 (43.9) 1.0 (Reference) 1.0 (Reference)
Asn/Ser 47 (42.0) 64 (56.1) 1.77 (1.05 - 2.99) 0.034b 2.03 (1.14 - 3.63) 0.016b
Oligoasthenozoospermia (n=67)
Ser/Ser 38 (33.9) 14 (20.9) 1.0 (Reference) 0.03a 1.0 (Reference) 0.02a
Co-dominant Asn/Ser 47 (42.0) 42 (62.79 2.43 (1.16-5.09) 0.02b 2.75 (1.24-6.07) 0.01b
Asn/Asn 27 (24.1) 11 (16.4) 1.11 (0.44-2.81) 0.83b 1.18 (0.44-3.18) 0.75b
Dominant Ser/Ser 38 (33.9) 14 (20.9) 1.0 (Reference) 1.0 (Reference)
Asn/Asn + Asn/Ser 74 (66.1) 53 (79.1) 1.94 (0.96 -3.94) 0.065b 2.18 (1.02 - 4.65) 0.045b
Recessive Ser/Ser +Asn/Ser 85 (75.9) 56 (83.6) 1.0 (Reference) 1.0 (Reference)
Asn/Asn 27 (24.1) 11 (16.4) 0.62 (0.28 - 1.35) 0.226b 0.60 (0.26 - 1.37) 0.224b
Over-dominant Ser/Ser + Asn/Asn 65 (58.0) 25 (37.3) 1.0 (Reference) 1.0 (Reference)
Asn/Ser 47 (42.0) 42 (62.7) 2.32 (1.25 - 4.32) 0.008b 2.56 (1.32 - 4.96) 0.006b
Normoasthenozoospermia (n=28)
Ser/Ser 38 (33.9) 5 (17.9) 1.0 (Reference) 0.22a 1.0 (Reference) 0.19a
Co-dominant Asn/Ser 47 (42.0) 13 (46.4) 2.10 (0.69-6.42) 0.19b 2.55 (0.76-8.56) 0.13b
Asn/Asn 27 (24.1) 10 (35.7) 2.82 (0.86-9.17) 0.09b 3.28 (0.87-12.30) 0.08b
Dominant Ser/Ser 38 (33.9) 5 (17.9) 1.0 (Reference) 1.0 (Reference)
Asn/Asn + Asn/Ser 74 (66.1) 23 (82.1) 2.36 (0.83 - 6.71) 0.106 2.80 (0.89 - 8.75) 0.077b
Recessive Ser/Ser +Asn/Ser 85 (75.9) 18 (64.3) 1.0 (Reference) 1.0 (Reference)
Asn/Asn 27 (24.1) 10 (35.79 1.75 (0.72 - 4.24) 0.216b 1.79 (0.66 - 4.89) 0.257b
Over-dominant Ser/Ser + Asn/Asn 65 (58.0) 15 (53.6) 1.0 (Reference) 1.0 (Reference)
Asn/Ser 47 (42.0) 13 (46.4) 1.20 (0.52 - 2.76) 0.670b 1.37 (0.55 - 3.41) 0.506b
Normospermia (n=19)
Ser/Ser 38 (33.9) 7 (36.8) 1.0 (Reference) 0.73a 1.0 (Reference) 0.58a
Co-dominant Asn/Ser 47 (42.0) 9 (47.4) 1.04 (0.35-3.05) 0.94b 1.15 (0.35-3.84) 0.82b
Asn/Asn 27 (24.1) 3 (15.8) 0.60 (0.14-2.55) 0.49b 0.53 (0.12-2.43) 0.41b
Dominant Ser/Ser 38 (33.9) 7 (36.8) 1.0 (Reference) 1.0 (Reference)
Asn/Asn + Asn/Ser 74 (66.1) 12 (63.2) 0.88 (0.32-2.42) 0.805b 0.88 (0.29 - 2.68) 0.822b
Recessive Ser/Ser +Asn/Ser 85 (75.9) 16 (84.2) 1.0 (Reference) 1.0 (Reference)
Asn/Asn 27 (24.1) 3 (15.8) 0.59 (0.16 - 2.18) 0.429b 0.49 (0.12 - 1.92) 0.305b
Over-dominant Ser/Ser + Asn/Asn 65 (58.0) 10 (52.6) 1.0 (Reference) 1.0 (Reference)
Asn/Ser 47 (42.0) 9 (47.4) 1.25 (0.47 - 3.30) 0.660b 1.48 (0.51 - 4.33) 0.470b
ORA = adjusted odds ratio (adjusted for age, body mass index, alcohol and smoking status) with 95% confidence interval (95% CI); aP values for overall genotype comparisons between the subgroups of infertile men and control group; bP values for individual comparisons with 
reference genotype between the subgroups of infertile men and control group; Bonferroni threshold for correction for multiple testing was 
estimated as Pc=0.0025 [Pc=0.05/20=0.0025, taking into account the number of study groups (five) and genotype models tested (four)]. Note: data for the subgroups of infertile men not shown.
Asn = asparagine; Ser = serine
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overall (P=0.0002) and oligoasthenozoospermic (P= 
0.0001) infertile men groups relative to control group 
(Table 1).
Regarding the effect of N680S FSHR polymor-
phism, we did not observe any statistically significant 
association of FSHR genotype frequencies with FSH 
serum levels in either control or any infertile men 
group analyzed (data not shown). Likewise, no signifi-
cant differences were found in LH, testosterone and 
prolactin hormone levels between men with different 
genotypes (Table 5).
The effects of N680S FSHR gene polymorphism  
on semen and testicular parameters
As expected, semen parameters (normal morphol-
ogy, concentration, total sperm count and progressive 
motility grade A and grade A+B) were significantly 
lower in the overall group, as well as in the oligo- and 
normo-asthenozoospermic infertile men subgroups 
when compared to controls. Notably, the progressive 
sperm motility grade A was also significantly lower in 
the normospermic infertile men group compared to 
control group. In addition, total testis volume showed 
significantly lower values in the overall group and oli-
goasthenozoospermic infertile men subgroup as com-
pared to control group (Table 1).
We also analyzed the effect of N680S FSHR poly-
morphism on major semen characteristics (sperm con-
centration, total sperm count, ejaculate volume, mor-
phology, total and progressive sperm motility grade A 
and grade A+B) and total testis volume. For that pur-
pose, data on testicular and seminal parameters in all 
study groups were pooled together to find variations 
among the different genotype models analyzed (Table 
5). As shown in Table 5, the co-dominant and over-
dominant genetic models once again implicated an 
increased risk of male infertility among the Asn/Ser 
(vs. Ser/Ser or Ser/Ser + Asn/Asn, respectively) geno-
type carriers regarding their lower values of major 
sperm parameters (i.e. percentage of cells with normal 
morphology, total sperm count and concentration, and 
grade A progressive and total mobility) analyzed (data 
for dominant and recessive genotype model are not 
shown). However, none of these associations remained 
significant after Bonferroni correction for multiple 
testing was applied [Pc=0.05/36=0.00138; taking into 
account the number of independent measurements 
(nine) and genotype models tested (four)].
Discussion
In the present study, infertile men and proven fer-
tile control subjects were genotyped to explore the as-
sociation between the N680S (rs6166 SNP; 2039A>G) 
FSHR gene polymorphism and male infertility risk in 
Albanian population from the Dukagjin region in the 
Republic of Kosovo. To the best of our knowledge, this 
was the first study examining the effect of FSHR gene 
polymorphism on male infertility parameters in Alba-
nian population. We found no significant difference in 
the distribution of N680S genotypes between the 
overall group of infertile men or oligoastheno-, nor-
moastheno- and normospermic infertile subgroups 
and the control group of fertile men. Our data agreed 
with those reported in the previous similar studies 
conducted in other ethnicities but there are differences 
in the proportions of genotype and allele distribution 
between our and others studies1,6,7,12,15,16. Namely, our 
study revealed the dominant frequency distribution of 
the Asn/Ser genotype to be consistent with its highest 
rates found in other ethnic groups1,6,7,12,15,16. However, 
contrary to other ethnic populations examined so far, 
the Ser/Ser variant in our population was represented 
at a higher frequency compared to Asn/Asn homozy-
gotes. Similar results have also been reported previ-
ously by our group concerning distribution of the 
FSHR ASn680Ser genotype variants in Albanian 
women from the same region17. The sociological and 
cultural features of the Albanian population, which are 
manifested by the low incidence of marital union with 
members of other ethnic groups, thus probably pre-
serving the genetic ‘pool’ originating from the indige-
nous population, may be responsible for this effect.
As a complex hormone-regulated disorder, male 
infertility is regulated by the hypothalamus-pituitary-
gonad axis with FSH, LH and testosterone as the 
prime regulators of germ cell development18,19. In our 
study, we found higher FSH and prolactin and lower 
LH and testosterone serum levels in the infertile men 
than in the control group men, but the difference 
reached statistical significance only for testosterone 
and prolactin serum levels in the overall group of in-
fertile men, and for testosterone levels in the oligoas-
thenozoospermic subgroup compared to control group.
In the infertile men, a higher concentration of FSH 
is usually a reliable indicator of severe germinal epithe-
lial damage, and was shown to be associated with azo-
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ospermia and severe oligozoospermia20,21. Likewise, 
low levels of serum LH and testosterone are found in 
men with oligoasthenozoospermia while hyperprolac-
tinemia causes infertility in around 11% of oligosper-
mic males22-25. Previous reports suggest that differences 
in the genotype and allele frequency of Asn680Ser 
FSHR polymorphic region might represent an impor-
tant genetic factor contributing to phenotypic expres-
sion of essential fertility parameters. This was clearly 
demonstrated for their influence on basal serum FSH 
concentrations in women, length and dynamics of 
menstrual cycle and effective FSH amount during 
ovarian stimulation for in vitro fertility techniques4,16. 
For example, women with the Ser/Ser receptor variant 
seem to be less sensitive to FSH stimulation and have 
significantly higher serum FSH levels in the follicular 
phase of the menstrual cycle than women with the 
Asn/Asn isoform26. The common FSHR polymor-
phisms in exon 10 and the promoter of FSHR gene 
have also been extensively studied in male infertility16. 
However, so far, there is no clear association of male 
infertility with the ASn680Ser FSHR polymorphic 
region. Most of the reports suggest no significant dif-
ferences in carrier frequencies of individual FSHR 
Asn680Ser polymorphic variants between infertile 
and fertile men from various ethnic groups6,8,9,27-36. The 
same results were obtained in a meta-analysis of these 
studies8-11. Similarly, the effect of Asn680Ser FSHR 
isoforms on clinical reproductive parameters such as 
FSH level, sperm count and total testis volume also 
failed to show any consistent associations16,28-30,33,34,37,38.
Like most of the previous reports, our study showed 
no statistically significant association of Asn680Ser 
FSHR genotype and allelic variants with serum FSH, 
LH, testosterone and prolactin levels in control and 
infertile men either. However, we did notice the in-
creased although nonsignificant risk of male infertility 
among heterozygous Asn/Ser (vs. Ser/Ser or Ser/Ser + 
Asn/Asn, respectively) genotype carriers regarding 
their lower values of major sperm parameters (total 
sperm count, concentration, morphology and motility) 
both in the overall group of infertile men and the in-
fertility subgroups based on various degrees of sper-
matogenic impairment.
A slight influence of the ASn680Ser FSHR gene 
polymorphism on male reproductive parameters has 
also been demonstrated recently by Grigorova et al.12. 
They detected significant association between the 
FSHR Ser680 allele and lower total testis volume in 
both the Baltic cohort of men and Estonian idiopathic 
infertility group12. Subsequent meta-analysis further 
supported their findings showing a moderate nonsig-
nificant effect between the FSHR Ser680 variant and 
higher serum FSH level, and significantly lower total 
testosterone levels. However, no statistically significant 
associations were identified with serum LH levels or 
with any of the sperm parameters12. A previous study 
in infertile men from Egyptian population reported by 
Zalata et al. also showed significantly higher serum 
FSH (Ser/Ser vs. Asn/Asn) and lower total serum tes-
tosterone (Asn/Ser and Ser/Ser vs. Asn/Asn) in 
Ser680 variant carriers13. They also detected a nonsig-
nificant decrease in sperm concentration, grade A and 
grade A + B progressive motility, and normal sperm 
morphology in Ser/Ser and Asn/Ser compared with 
the Asn/Asn genotype form13. Furthermore, Tsitlaki-
dis et al. have recently reported on a significant asso-
ciation of heterozygous Asn/Ser genotype form with 
different size of the right testis in infertile Greek men 
but no association of any genotype form with hormon-
al serum levels (FSH, LH, testosterone, and prolactin) 
or sperm parameters (semen volume, sperm count, 
morphology and motility) was detected14. In addition, 
a recent meta-analysis reported by Wu et al. detected 
association of Asn680Ser FSHR Ser/Ser genotype 
form (Ser/Ser vs. Asn/Asn and Ser/Ser vs. Asn/Asn + 
Asn/Ser) with an increased risk of male infertility7. 
One of the main reasons for the observed differences 
between their results and the findings of our study re-
garding the overall influence of the ASn680Ser FSHR 
gene polymorphism on infertility status and identifi-
cation of effective genotype responsible for modifica-
tion of sperm parameters can be found in population 
stratification and ethnic and geographic variation, but 
additional genetic and environmental factors cannot 
be excluded. Since the phenotypic effects of individual 
polymorphism may be modulated by the overall ge-
netic background, a combined effect of other polymor-
phic regions and ASn680Ser allele and genotype vari-
ants on male infertility should also be examined.
For example, Wu et al. report that homozygous 
combination of FSHR gene polymorphism at codon 
307 and 680 (i.e. Thr/Thr + Asn/Asn) may be respon-
sible for male infertility in patients from north Chi-
na11. In addition, Lindgren et al. report that Thr307-
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Asn680 homozygotes in a Swedish cohort of young 
men among others exhibited lower serum FSH and 
higher total testosterone concentrations, as well as 
larger testis volume and higher sperm count when 
compared with heterozygotes and Ala307-Ser680 ho-
mozygote carriers39. The discrete codon combination 
with homo/heterozygous variation of the Thr307Ala 
and Asn680Ser FSHR gene polymorphisms has also 
been reported in other Asian ( Japan and China) and 
non-Asian (i.e. Italian, German, Egyptian, Estonian, 
Turkish, Iranian and Brazilian populations) patient 
groups8,11-13,28-31,33-35,37,38. A synergistic effect of FSHR 
promoter polymorphic region (2039A>G) and other 
genetic loci (e.g., FSHB-211G>T) with Thr307Ala/
Asn680Ser allelic variants has also been reported7,36,40.
Conclusion
Our study revealed the increased risk of male infer-
tility among the Asn/Ser (vs. Ser/Ser or Ser/Ser + 
Asn/Asn) genotype carriers in the group of infertile 
men as a whole or when subgrouping them according 
to various degrees of spermatogenetic impairment. 
Further studies on a larger population and haplotype-
based association analysis instead of single SNP test-
ing are required to confirm our findings in a more de-
finitive fashion.
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Sažetak
POJAVNOST GENSKOG POLIMORFIZMA RECEPTORA 2039A>G FOLIKULARNO  
STIMULIRAJUĆEG HORMONA I RIZIK MUŠKE NEPLODNOSTI U ALBANSKOJ POPULACIJI
E. Shkelzen, F. Paić, F. Stipoljev, Z. Gashi, A. Zeqiraj, A. Lila i T. Nikuševa Martić
Cilj ovoga istraživanja bio je odrediti pojavnost alela i varijante genotipa receptora folikularno stimulirajućeg hormona 
(FSHR) na poziciji Asn680Ser kod muškaraca albanske populacije u odnosu na kliničke parametre neplodnosti. Istraživanje 
je obuhvatilo 114 neplodnih muškaraca (srednja dob 35,04±5,85 godina) svrstanih prema razini oštećenja spermiograma 
(oligoastenozoospermija, astenozoospermija i normospermija) te 112 plodnih muškaraca (srednja dob 36,44±7,05 godina) s 
urednim nalazom spermiograma. Genotipizacija gena FSHR na poziciji 680 učinjena je primjenom TaqMan probe. Kod svih 
sudionika istraživanja učinjena je analiza sjemena i reprodukcijskih hormona uključujući FSH, luteinizirajući hormon, pro-
laktin i testosteron. U kontrolnoj skupini ispitanika kod FSHR Asn680Ser genotipa utvrđena pojavnost Asn/Ser bila je 42%, 
Ser/Ser 33,9% i Asn/Asn 24,1%, dok se u skupini neplodnih ispitanika incidencija kretala od 56,1% za Asn/Ser, 22,8% za 
Ser/Ser i 21,1% za Asn/Asn (χ2-test; p=0,08). Nije ustanovljena značajna statistička povezanost između razine hormona, 
karakteristika sjemena, stanja plodnosti u varijanti gena FSHR Asn680Ser u kontrolnoj skupini u odnosu na ispitanike u 
skupini neplodnih muškaraca. Ipak, primjenom prilagođene, logističke i regresijske analize (dob, indeks tjelesne mase, puše-
nje i alkohol kao kovarijable) utvrđeno je da postoji veća vjerojatnost javljanja muške neplodnosti kod nositelja heterozigota 
Asn/Ser koji su povezani sa sniženim vrijednostima parametara sjemena (morfologija, koncentracija, ukupan broj i pokretlji-
vost). Zaključno možemo utvrditi da ovo istraživanje potvrđuje ranija izvješća kako ne postoji značajna povezanost između 
polimorfizma FSHR Asn680Ser i muške neplodnosti. Ipak, navedeni podaci upućuju na to da Asn/Ser genotip može povi-
siti rizik muške neplodnosti u albanskoj populaciji.
Ključne riječi: Neplodnost muškarca; Prolaktin; Testosteron; Receptori, FSH; Studije slučajeva i kontrola
